Sanofi-aventis announced the results of the first placebo-controlled study of the GetGoal Phase III clinical trial program of lixisenatide (AVE0010), a once-daily GLP-1 agonist developed for patients with type 2 diabetes. The 12-week study involved 361 patients with type 2 diabetes not currently receiving glucose-lowering therapy...

A new study out of the University of Oxford has found a genetic link between low birth weight and the development of type 2 diabetes. According to the BBC most of the existing has research focused on environmental factors when trying to explain the connection between lower birth weight and risk of developing type 2 diabetes. The...

A new study out of Hong Kong suggests that soy supplements do not benefit type 2 diabetics. According to a Reuters report, previous lab research has suggested that soy proteins and soy isoflavones — “phytoestrogen” compounds that are structurally similar to human estrogen — may help control blood sugar levels....

According to a Novo Nordisk announcement the results from their LEAD™ 6 extension study show that switching to once-daily Victoza® (Liraglutide [rDNA Origin] Injection) from exenatide improves blood sugar control in patients with type 2 diabetes. The study published online in Diabetes Care evaluated the efficacy and safety of switching...

Many studies have shown that drinking coffee, regular or decaf, with or without sugar, reduces the risk of developing type 2 diabetes. A new study, reported by the Globe and Mail has found that when you drink your coffee may have an effect on diabetes risk. The researchers studied 69,532 French women, aged 41 to 72, to investigate...

Takeda Pharmaceutical Company Limited announced today that its wholly-owned subsidiary Takeda Global Research & Development Centre (Europe) Ltd.  withdrew a European Marketing Authorization Application (MAA) for Competact®, a prolonged-release formulation of its combination treatment for type 2 diabetes. Takeda also decided...

Bristol-Myers Squibb Company and AstraZeneca announced that the U.S. Food and Drug Administration has accepted for review a New Drug Application (NDA) for an once daily fixed dose combination of ONGLYZA™ (saxagliptin) and metformin HCI extended-release tablets as a once-daily treatment for type 2 diabetes mellitus...

An Ohio State University study found that an experimental oral drug lowers blood sugar levels and inflammation in mice with type 2 diabetes, suggesting that the medication could someday be used to treat humans with type 2 diabetes. The drug consists of a synthetic molecule that stops the biological activity of a protein called...

Amylin Pharmaceuticals Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for BYDUREON(TM). In the complete response letter there are no requests for new pre-clinical or clinical trials. Requests...

The earlier patients diagnosed with type 2 diabetes started taking metformin, the longer the drug remained effective, says a new study, published in Diabetes Care. The study reported by EurekAlert used electronic health records to follow nearly 1,800 people with diabetes in Kaiser Permanente’s health plan in Washington and...